首页> 外文期刊>Archives of gynecology and obstetrics. >Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women.
【24h】

Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women.

机译:序贯联合经皮和口服激素替代疗法对绝经后妇女血清脂质和脂蛋白的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to compare the effects of sequential combined transdermal and oral postmenopausal hormone replacement therapies on serum lipid-lipoprotein profiles risk markers for cardiovascular disease. A prospective randomize study was designed: Ninety-six healthy nonhysterectomised postmenopausal women were randomized to receive either transdermal continuous 17beta-estradiol, 0.05 mg/d (Estraderm TTS, Novartis, Basel, Switzerland), with transdermal sequential norethisterone acetate, 0.25 mg/d (Estragest TTS, Novartis, Basel, Switzerland), or oral continuous conjugated equine estrogens, 0.625 mg/d (Premarin 0.625 mg, Wyeth, Philadelphia, U.S.A.), with oral sequential medroxyprogesterone acetate, 10 mg/d (Farlutal 5 mg, Deva, Istanbul, Turkey). 84 women completed the trial, 42 in oral and 42 in the transdermal group. The serum levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, apolipoproteins AI and apolipoproteins B at 6 months after starting treatment were compared with baseline values for both therapies. Both oral and transdermal therapies significantly reduced serum levels of total cholesterol (208-190 mg/dL and 216-199 mg/dL, respectively, p=0.0001) and LDL-cholesterol (128-112 mg/dL and 140-127 mg/dL, respectively, p=0.001). The serum levels of triglycerides did not show any significant change with oral therapy, whereas this lipid fell (128-101 mg/dL, p=0.0001) significantly with transdermal therapy. We found significant decrease in HDL-cholesterol with transdermal therapy while there was no significant change with oral therapy. Apolipoproteins AI, the major protein component of HDL2 subfraction, was increased by oral therapy and lowered by transdermal therapy. As a conclusion, we have found that serum total cholesterol and LDL-cholesterol were lowered by both therapies, with no significant differences between treatments, whereas there were significant differences between treatments according to effects on serum triglycerides and apolipoproteins AI.
机译:这项研究的目的是比较连续经皮和绝经后口服激素替代疗法联合治疗对心血管疾病患者血清脂质-脂蛋白谱危险指标的影响。设计了一项前瞻性随机研究:将96名健康的非子宫切除术的绝经后妇女随机接受经皮连续17beta-雌二醇0.05 mg / d(Estraderm TTS,诺华,巴塞尔,瑞士)和经皮顺式醋酸炔诺酮0.​​25 mg / d。 (Estragest TTS,诺华,巴塞尔,瑞士),或口服连续共轭马雌激素0.625 mg / d(Premarin 0.625 mg,Wyeth,美国费城),口服醋酸顺序甲羟孕酮10 mg / d(Farlutal 5 mg,Deva) , 伊斯坦布尔,土耳其)。 84名妇女完成了该试验,其中42例口服,透皮组42例。在开始治疗后6个月,将总胆固醇,LDL-胆固醇,HDL-胆固醇,甘油三酸酯,载脂蛋白AI和载脂蛋白B的血清水平与两种疗法的基线值进行比较。口服和经皮治疗均显着降低血清总胆固醇水平(分别为208-190 mg / dL和216-199 mg / dL,p = 0.0001)和LDL-胆固醇(128-112 mg / dL和140-127 mg / d)。 dL,p = 0.001)。口服疗法的血清甘油三酸酯水平未显示任何显着变化,而经皮疗法的血脂显着下降(128-101 mg / dL,p = 0.0001)。我们发现经皮疗法可显着降低HDL-胆固醇,而口服疗法则无明显变化。载脂蛋白AI是HDL2亚组分的主要蛋白成分,通过口服治疗可增加,而经皮治疗则可降低。结论是,我们发现两种疗法均降低了血清总胆固醇和LDL-胆固醇,治疗之间无显着差异,而根据对血清甘油三酸酯和载脂蛋白AI的影响,治疗之间也存在显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号